A Phase 3 interventional study of NVA237 50µg once daily and Tiotropium 18µg once daily in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 68 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-01-05.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 16th largest by enrollment, is one of 11 that started in 2012, is one of 33 in phase 3, and was the 20th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 773 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 24th largest by enrollment of the 116 interventional ones that give a count, is one of 22 that started in 2012, is one of 59 in phase 3, and was the 61st registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy, tolerability and safety of NVA237 compared to tiotropium when added on to fluticasone/salmeterol in patients with chronic obstructive pulmonary disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NVA237 50 µg once daily (NVA237 + Tiotropium placebo + Flu/Sal). NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI) o.d. plus Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
Drug: NVA237 50µg once daily · Drug: Flu/Sal · Drug: NVA237 placebo + Tiotropium placebo.
Tiotropium 18µg once daily (NVA237 placebo + Tiotropium + Flu/Sal). Tiotropium 18 μg o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
Drug: Tiotropium 18µg once daily · Drug: Flu/Sal · Drug: NVA237 placebo + Tiotropium placebo.
Placebo (NVA237 placebo + Tiotropium placebo + Flu/Sal). Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
Drug: Flu/Sal · Drug: NVA237 placebo + Tiotropium placebo.
NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI)
Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device
Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
Change From Baseline in Mean Trough Forced Expiratory Volume in 1 Second (FEV1) (NVA237 Versus Tiotropium)
Spirometry was conducted according to internationally accepted standards. Trough FEV1 referred to the mean of FEV1 at 23:15 hours and 23:45 hours after the morning dose of study drug. The baseline was defined as the average of FEV1 values taken in the clinic 45 min and 15 min prior to the first dose of randomized treatment at Visit 3. A mixed model was used and contained treatment as a fixed effect with the baseline measurement of trough FEV1, FEV1 prior to inhalation of short acting bronchodilators, and FEV1 post-inhalation of bronchodilators and stratification factors as covariates. A positive change from baseline indicates improvement.
Time frame: baseline, 12 weeks
Change From Baseline in Mean Trough FEV1 (Flu/Sal Versus NVA237/Tiotropium+Flu/Sal)
Spirometry was conducted according to internationally accepted standards. Trough FEV1 referred to the mean of FEV1 at 23:15h and 23:45h after the morning dose of study drug. The baseline was defined as the average of FEV1 values taken in the clinic 45min and 15min prior to the first dose of randomized treatment at Visit 3. A mixed model was used and contained treatment as a fixed effect with the baseline measurement of trough FEV1, FEV1 prior to inhalation of short acting bronchodilators, and FEV1 post-inhalation of bronchodilators and stratification factors as covariates. A positive change from baseline indicates improvement.
Time frame: baseline, 4 weeks, 8 weeks, 12 weeks
Change From Baseline in Mean Trough FEV1
Spirometry was conducted according to internationally accepted standards. Trough FEV1 referred to the mean of FEV1 at 23:15h and 23:45h after the morning dose of study drug. The baseline was defined as the average of FEV1 values taken in the clinic 45min and 15min prior to the first dose of randomized treatment at Visit 3. A mixed model was used and contained treatment as a fixed effect with the baseline measurement of trough FEV1, FEV1 prior to inhalation of short acting bronchodilators, and FEV1 post-inhalation of bronchodilators and stratification factors as covariates. A positive change from baseline indicates improvement.
Time frame: baseline, 4 weeks, 8 weeks, 12 weeks
Change From Baseline in Total Score of the St George's Respiratory Questionnaire for COPD Patients (SGRQ-C) After 12 Weeks of Treatment
SGRQ-C is a health related quality of life questionnaire consisting of 40 items divided into two components: 1) symptoms, 2) activity\& impacts. The lowest possible value is zero and the highest is 100. Higher values corresponded to greater impairment in quality of life. An analysis model included terms for treatment, baseline total SGRQ score, FEV1 and baseline smoking status. The model also contained as fixed effects the baseline total SGRQ score, FEV1 prior to inhalation of short acting bronchodilator, FEV1 post inhalation of short acting bronchodilator and stratification factors as covariates. A negative change from baseline indicates improvement.
Time frame: 12 weeks
Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Use
The total number of puffs of rescue medication used over the last 12 h recorded in the morning (nighttime use) and in the evening (daytime use) over the full 12 weeks was divided by the total number of days with non-missing rescue data to derive the mean daytime and nighttime number of puffs of rescue medication. Change from baseline in the mean daytime and nighttime number of puffs of rescue medication was analyzed as for the change from baseline in the mean daily number of puffs of rescue medication.
Time frame: baseline, 12 weeks
Mean Percentage of Nights With 'no Nighttime Awakenings'
A night with 'no nighttime awakenings' is defined from diary data as any night where patient did not wake up due to symptoms. Total number of nights with 'no nighttime awakenings' over treatment period was divided by total number of nights where diary recordings have been made in order to derive percentage of 'no nighttime awakenings' which will be summarized by treatment and analyzed using a similar mixed model as specified for primary analysis. Diary data recorded during the 7 day run-in period was used to calculate baseline percentage of nights 'no nighttime awakenings'.
Time frame: 12 weeks
Mean Percentage of Days With Performance of Usual Activities
A 'day able to perform usual daily activities' was defined from diary data as any day where the patient was not prevented from performing their usual daily activities due to respiratory symptoms. The percentage of 'days able to perform usual daily activities' was derived and analyzed using a similar mixed model as specified for primary analysis as for the percentage of nights with 'no nighttime awakenings'.
Time frame: 12 weeks
| Milestone | NVA237 + Fluticasone/Salmeterol (Flu/Sal) | Tiotropium + Flu/Sal | Flu/Sal |
|---|---|---|---|
| Started | 258 | 258 | 257 |
| Full analysis set | 257 | 258 | 257 |
| Per-protocol set | 196 | 186 | 166 |
| Completed | 229 | 226 | 201 |
| Not completed | 29 | 32 | 56 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Abnormal laboratory value | 1 | 0 | 1 |
| Withdrew: Lack of efficacy | 1 | 2 | 5 |
| Withdrew: Protocol deviations | 3 | 4 | 3 |
| Withdrew: Withdrawal by subject | 7 | 8 | 21 |
| Withdrew: Adverse event | 16 | 18 | 23 |
| Withdrew: Abnormal test procedure | 1 | 0 | 0 |
Spirometry was conducted according to internationally accepted standards. Trough FEV1 referred to the mean of FEV1 at 23:15 hours and 23:45 hours after the morning dose of study drug. The baseline was defined as the average of FEV1 values taken in the clinic 45 min and 15 min prior to the first dose of randomized treatment at Visit 3. A mixed model was used and contained treatment as a fixed effect with the baseline measurement of trough FEV1, FEV1 prior to inhalation of short acting bronchodilators, and FEV1 post-inhalation of bronchodilators and stratification factors as covariates. A positive change from baseline indicates improvement.
| liters | NVA237 + Fluticasone/Salmeterol (Flu/Sal) | Tiotropium + Flu/Sal |
|---|---|---|
| Change From Baseline in Mean Trough Forced Expiratory Volume in 1 Second (FEV1) (NVA237 Versus Tiotropium) | 0.095 ± 0.0131 | 0.102 ± 0.0135 |
Spirometry was conducted according to internationally accepted standards. Trough FEV1 referred to the mean of FEV1 at 23:15h and 23:45h after the morning dose of study drug. The baseline was defined as the average of FEV1 values taken in the clinic 45min and 15min prior to the first dose of randomized treatment at Visit 3. A mixed model was used and contained treatment as a fixed effect with the baseline measurement of trough FEV1, FEV1 prior to inhalation of short acting bronchodilators, and FEV1 post-inhalation of bronchodilators and stratification factors as covariates. A positive change from baseline indicates improvement.
| Liters | Flu/Sal | NVA237/Tiotropium+Flu/Sal |
|---|---|---|
| Week 4 | -0.010 ± 0.0099 | 0.077 ± 0.0073 |
| Week 8 | -0.002 ± 0.0099 | 0.088 ± 0.0073 |
| Week 12 | -0.012 ± 0.0099 | 0.088 ± 0.0073 |
Spirometry was conducted according to internationally accepted standards. Trough FEV1 referred to the mean of FEV1 at 23:15h and 23:45h after the morning dose of study drug. The baseline was defined as the average of FEV1 values taken in the clinic 45min and 15min prior to the first dose of randomized treatment at Visit 3. A mixed model was used and contained treatment as a fixed effect with the baseline measurement of trough FEV1, FEV1 prior to inhalation of short acting bronchodilators, and FEV1 post-inhalation of bronchodilators and stratification factors as covariates. A positive change from baseline indicates improvement.
| Liters | NVA237 + Fluticasone/Salmeterol (Flu/Sal) | Tiotropium + Flu/Sal | Flu/Sal |
|---|---|---|---|
| Week 4 | 0.077 ± 0.0100 | 0.077 ± 0.0101 | -0.010 ± 0.0099 |
| Week 8 | 0.084 ± 0.0100 | 0.092 ± 0.0101 | -0.002 ± 0.0099 |
| Week 12 | 0.089 ± 0.0100 | 0.087 ± 0.0101 | -0.012 ± 0.0099 |
SGRQ-C is a health related quality of life questionnaire consisting of 40 items divided into two components: 1) symptoms, 2) activity\& impacts. The lowest possible value is zero and the highest is 100. Higher values corresponded to greater impairment in quality of life. An analysis model included terms for treatment, baseline total SGRQ score, FEV1 and baseline smoking status. The model also contained as fixed effects the baseline total SGRQ score, FEV1 prior to inhalation of short acting bronchodilator, FEV1 post inhalation of short acting bronchodilator and stratification factors as covariates. A negative change from baseline indicates improvement.
| units on a scale | NVA237 + Fluticasone/Salmeterol (Flu/Sal) | Tiotropium + Flu/Sal | Flu/Sal |
|---|---|---|---|
| Change From Baseline in Total Score of the St George's Respiratory Questionnaire for COPD Patients (SGRQ-C) After 12 Weeks of Treatment | -2.806 ± 0.6772 | -3.902 ± 0.6920 | -0.652 ± 0.6871 |
The total number of puffs of rescue medication used over the last 12 h recorded in the morning (nighttime use) and in the evening (daytime use) over the full 12 weeks was divided by the total number of days with non-missing rescue data to derive the mean daytime and nighttime number of puffs of rescue medication. Change from baseline in the mean daytime and nighttime number of puffs of rescue medication was analyzed as for the change from baseline in the mean daily number of puffs of rescue medication.
| puffs of rescue medication | NVA237 + Fluticasone/Salmeterol (Flu/Sal) | Tiotropium + Flu/Sal | Flu/Sal |
|---|---|---|---|
| Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Use | 2.191 ± 0.1384 | 2.093 ± 0.1397 | 2.908 ± 0.1395 |
A night with 'no nighttime awakenings' is defined from diary data as any night where patient did not wake up due to symptoms. Total number of nights with 'no nighttime awakenings' over treatment period was divided by total number of nights where diary recordings have been made in order to derive percentage of 'no nighttime awakenings' which will be summarized by treatment and analyzed using a similar mixed model as specified for primary analysis. Diary data recorded during the 7 day run-in period was used to calculate baseline percentage of nights 'no nighttime awakenings'.
| Percentage of nights | NVA237 + Fluticasone/Salmeterol (Flu/Sal) | Tiotropium + Flu/Sal | Flu/Sal |
|---|---|---|---|
| Mean Percentage of Nights With 'no Nighttime Awakenings' | 0.834 ± 0.0124 | 0.816 ± 0.0124 | 0.823 ± 0.0124 |
A 'day able to perform usual daily activities' was defined from diary data as any day where the patient was not prevented from performing their usual daily activities due to respiratory symptoms. The percentage of 'days able to perform usual daily activities' was derived and analyzed using a similar mixed model as specified for primary analysis as for the percentage of nights with 'no nighttime awakenings'.
| Percentage of days | NVA237 + Fluticasone/Salmeterol (Flu/Sal) | Tiotropium + Flu/Sal | Flu/Sal |
|---|---|---|---|
| Mean Percentage of Days With Performance of Usual Activities | 0.934 ± 0.0087 | 0.946 ± 0.0088 | 0.903 ± 0.0088 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NVA237 + Fluticasone/Salmeterol (Flu/Sal) | — | 15/257 (5.8%) | 114/257 (44.4%) |
| Tiotropium + Flu/Sal | — | 22/258 (8.5%) | 124/258 (48.1%) |
| Flu/Sal | — | 15/257 (5.8%) | 111/257 (43.2%) |
| Event | NVA237 + Fluticasone/Salmeterol (Flu/Sal) | Tiotropium + Flu/Sal | Flu/Sal |
|---|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 2/257 | 0/258 | 0/257 |
| PneumoniaInfections and infestations | 0/257 | 2/258 | 2/257 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/257 | 1/258 | 2/257 |
| Atrial fibrillationCardiac disorders | 0/257 | 2/258 | 1/257 |
| AnaemiaBlood and lymphatic system disorders | 0/257 | 0/258 | 1/257 |
| Acute coronary syndromeCardiac disorders | 0/257 | 1/258 | 1/257 |
| Angina pectorisCardiac disorders | 0/257 | 1/258 | 1/257 |
| Atrial flutterCardiac disorders | 1/257 | 1/258 | 0/257 |
| Ventricular fibrillationCardiac disorders | 0/257 | 0/258 | 1/257 |
| VertigoEar and labyrinth disorders | 1/257 | 0/258 | 0/257 |
| Event | NVA237 + Fluticasone/Salmeterol (Flu/Sal) | Tiotropium + Flu/Sal | Flu/Sal |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 17/257 | 13/258 | 11/257 |
| CoughRespiratory, thoracic and mediastinal disorders | 16/257 | 15/258 | 11/257 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 6/257 | 15/258 | 5/257 |
| HeadacheNervous system disorders | 3/257 | 4/258 | 13/257 |
| Oral candidiasisInfections and infestations | 12/257 | 13/258 | 9/257 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 11/257 | 9/258 | 5/257 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 9/257 | 10/258 | 8/257 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/257 | 8/258 | 9/257 |
| Dry mouthGastrointestinal disorders | 5/257 | 9/258 | 2/257 |
| NauseaGastrointestinal disorders | 3/257 | 9/258 | 3/257 |
| Age, Continuous(Years) | NVA237 + Fluticasone/Salmeterol (Flu/Sal) | Tiotropium + Flu/Sal | Flu/Sal | Total |
|---|---|---|---|---|
| Mean | 68.2 ± 8.38 | 68.0 ± 7.74 | 67.8 ± 8.49 | 68.0 ± 8.20 |
| Sex: Female, Male(Participants) | NVA237 + Fluticasone/Salmeterol (Flu/Sal) | Tiotropium + Flu/Sal | Flu/Sal | Total |
|---|---|---|---|---|
| Female | 94 | 98 | 83 | 275 |
| Male | 163 | 160 | 174 | 497 |
The record gives a start of Apr 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →